AU2002316318A1 - Antisense modulation of transforming growth factor beta receptor ii expression - Google Patents

Antisense modulation of transforming growth factor beta receptor ii expression

Info

Publication number
AU2002316318A1
AU2002316318A1 AU2002316318A AU2002316318A AU2002316318A1 AU 2002316318 A1 AU2002316318 A1 AU 2002316318A1 AU 2002316318 A AU2002316318 A AU 2002316318A AU 2002316318 A AU2002316318 A AU 2002316318A AU 2002316318 A1 AU2002316318 A1 AU 2002316318A1
Authority
AU
Australia
Prior art keywords
expression
growth factor
transforming growth
factor beta
beta receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002316318A
Other languages
English (en)
Inventor
Susan F. Murray
Jacqueline R. Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AU2002316318A1 publication Critical patent/AU2002316318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2002316318A 2001-06-21 2002-06-19 Antisense modulation of transforming growth factor beta receptor ii expression Abandoned AU2002316318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/888,361 2001-06-21
US09/888,361 US20030064944A1 (en) 2001-06-21 2001-06-21 Antisense modulation of transforming growth factor beta receptor II expression
PCT/US2002/019665 WO2003000656A2 (en) 2001-06-21 2002-06-19 Antisense modulation of transforming growth factor beta receptor ii expression

Publications (1)

Publication Number Publication Date
AU2002316318A1 true AU2002316318A1 (en) 2003-01-08

Family

ID=25393053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002316318A Abandoned AU2002316318A1 (en) 2001-06-21 2002-06-19 Antisense modulation of transforming growth factor beta receptor ii expression

Country Status (5)

Country Link
US (2) US20030064944A1 (enExample)
EP (1) EP1406915A4 (enExample)
JP (1) JP2005504522A (enExample)
AU (1) AU2002316318A1 (enExample)
WO (1) WO2003000656A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
US6784291B2 (en) * 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
JP2007502284A (ja) * 2003-08-13 2007-02-08 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ｓｉＲＮＡによるＴＧＦベータＩＩ型受容体発現のサイレンシング
RU2385933C2 (ru) * 2004-02-09 2010-04-10 Реженьон Гмбх Ингибиторы передачи сигнала трансформирующих факторов роста (tgf-r) для лечения расстройств цнс
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
WO2008109546A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
AU2008324066A1 (en) * 2007-11-05 2009-05-14 Baltic Technology Development, Ltd. Use of oligonucleotides with modified bases as antiviral agents
US20110159035A1 (en) * 2008-08-01 2011-06-30 Masahiro Goto S/o type transdermal immunizing agent
RS59182B1 (sr) * 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
US11028390B2 (en) * 2017-07-10 2021-06-08 Osaka University Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
CN111788216B (zh) * 2017-12-18 2023-06-23 森正之 盐泡细胞形成控制作用剂和导入了该作用剂的植物体
WO2021163281A1 (en) * 2020-02-12 2021-08-19 Accutar Biotechnology Inc. Antisense oligonucleotides and their use for treating pendred syndrome
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein

Also Published As

Publication number Publication date
JP2005504522A (ja) 2005-02-17
WO2003000656A2 (en) 2003-01-03
EP1406915A2 (en) 2004-04-14
WO2003000656A3 (en) 2003-02-27
US20030064944A1 (en) 2003-04-03
US20040147472A1 (en) 2004-07-29
EP1406915A4 (en) 2006-10-04

Similar Documents

Publication Publication Date Title
AU2002360467A1 (en) Antisense modulation of connective tissue growth factor expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU4200400A (en) Antisense oligonucleotide modulation of stat3 expression
AU2001289046A1 (en) Antisense modulation of her-2 expression
AU5490500A (en) Antisense modulation of beta catenin expression
AU2002316318A1 (en) Antisense modulation of transforming growth factor beta receptor ii expression
AU2003283966A1 (en) Antisense modulation of farnesoid x receptor expression
AU6296199A (en) Antisense modulation of smad1 expression
AU2002364125A1 (en) Antisense modulation of mdm2 expression
AU1245001A (en) Antisense modulation of nucleolin expression
AU6115400A (en) Antisense modulation of mekk5 expression
AU2002320525A1 (en) Antisense modulation of glioma-associated oncogene-2 expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2001268307A1 (en) Antisense modulation of c/ebp beta expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2213600A (en) Antisense modulation of mdmx expression
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2002346632A1 (en) Antisense modulation of mhc class ii transactivator expression
AU2002353076A1 (en) Antisense modulation of estrogen receptor beta expression
AU2002347809A1 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
AU2002319635A1 (en) Antisense modulation of short heterodimer partner-1 expression
AU2002341548A1 (en) Antisense modulation of transforming growth factor-beta 3 expression
AU2002330953A1 (en) Antisense modulation of cyclin d2 expression
AU6109900A (en) Antisense modulation of shp-1 expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase